The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,022
Hsieh, J. J.-D., Le, V. H., Oyama, T., Ricketts, C. J., Ho, T. H., & Cheng, E. H. Y. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2549 · Cited by 194
Saleh, K., Daste, A., Martin, N., Tostivint, E. P., Auperin, A., Gómez, R. G. H., Baste-Rotllan, N., Bidault, F., Guigay, J., Tourneau, C. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.026 · Cited by 189
(ECIL), O. B. O. T. E. C. O. I. I. L., Maschmeyer, G., Greef, J. D., Mellinghoff, S. C., Nosari, A., Thiébaut, A., Bergeron, A., Franquet, T., Blijlevens, N. M. A., & Maertens, J. A. (2019) · Leukemia · doi:10.1038/s41375-019-0388-x · Cited by 188
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot, J., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.-L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.014 · Cited by 184
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 185
Alva, A. S., Mangat, P. K., Garrett-Mayer, E. S., Halabi, S., Hansra, D. M., Calfa, C. J., Khalil, M. F., Ahn, E. R., Cannon, T. L., Crilley, P. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02923 · Cited by 188
Powles, T. B., Albiges, L. K., Staehler, M. D., Bensalah, K., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T. B. L., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.11.016 · Cited by 182
George, S., Motzer, R. J., Hammers, H. J., Redman, B. G., Kuzel, T. M., Tykodi, S. S., Plimack, E. R., Jiang, J., Waxman, I. M., & Rini, B. I. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0775 · Cited by 182
Self-citationChuzi, S. E., Tavora, F. R. F., Cruz, M. R. D. S., Costa, R. L. B., Chae, Y. K., Carneiro, B. A., & Giles, F. J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s136818 · Cited by 181
Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181
Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M. A., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0420-0 · Cited by 183
Self-citationCurrent issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179
Bhindi, B., Abel, E. J., Albiges, L. K., Bensalah, K., Boorjian, S. A., Daneshmand, S., Karam, J. A., Mason, R. J., Powles, T. B., & Bex, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.016 · Cited by 179
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 183
Self-citationDual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 182
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L., Hohlfeld, R., & Liblau, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 178
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
Wang, Z., He, L., Li, W., Xu, C., Zhang, J., Wang, D., Dou, K., Zhuang, R., Jin, B., Zhang, W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002787 · Cited by 178
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
The role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L. G. T., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A.-T. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 178
Costa, R. L. B., Shah, A. N., Santa-Maria, C. A., Cruz, M. R. D. S., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.010 · Cited by 177
Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N. A., & Pentheroudakis, G. E. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 175
Zucali, P. A., Pas, T. M. D., Palmieri, G., Favaretto, A. G., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., Vincenzo, F. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4078 · Cited by 175
Systemic treatment of renal cell cancer: A comprehensive review
Sánchez-Gastaldo, A., Kempf, E., del Alba, A. G., & Durán, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.010 · Cited by 178
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Yuan, H., Jiang, W., Roemeling, C. A. V., Qie, Y., Liu, X., Chen, Y., Wang, Y., Wharen, R. E., Yun, K., Bu, G., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.69 · Cited by 173
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 180
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 182
Emerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 175
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 175
Chiu, D. K., Yuen, V. W., Cheu, J. W., Wei, L. L., Ting, V., Fehlings, M., Sumatoh, H., Nardin, A., Newell, E. W., Ng, I. O., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.074 · Cited by 171
PD-1 blockade enhances the vaccination-induced immune response in glioma
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J. R., Moughon, D. L., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87059 · Cited by 173
Genomic profiling in renal cell carcinoma
Dizman, N., Philip, E. J., & Pal, S. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0301-x · Cited by 171
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Bakouny, Z., Braun, D. A., Shukla, S. A., Pan, W., Gao, X. Y., Hou, Y., Flaifel, A., Tang, S., Bosma-Moody, A., He, M. X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21068-9 · Cited by 174
Self-citationHaanen, J. B. A. G., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I. J., Grivas, P. D., Larkin, J., Peters, S., Thompson, J. A., & Obéid, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000604 · Cited by 174
Self-citationRacial and ethnic disparities in hematologic malignancies
Kirtane, K., & Lee, S. J. (2017) · Blood · doi:10.1182/blood-2017-04-778225 · Cited by 168
Advances in Cancer Immunotherapy in Solid Tumors
Menon, S. P., Shin, S. J., & Dy, G. K. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 170
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Choueiri, T. K., Powles, T. B., Albiges, L. K., Burotto, M., Szczylik, C. A., Żurawski, B. A., Ruiz, E. Y., Maruzzo, M., Zaizar, A. S., Fein, L. E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212851 · Cited by 171
Self-citationUdager, A. M., Liu, T., Skala, S. L., Magers, M. J., McDaniel, A. S., Spratt, D. E., Feng, F. Y.-C., Siddiqui, J., Cao, X., Fields, K. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw216 · Cited by 167
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12677 · Cited by 168
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M. M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D. E., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 168
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 173
Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 171
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease
Kitchlu, A., Jhaveri, K. D., Wadhwani, S., Deshpande, P. P., Harel, Z., Kishibe, T., Henriksen, K., & Wanchoo, R. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.10.002 · Cited by 167
Wang, T., Lü, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 165
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A. C., Flietner, E., Morrow, Z. T., Chaudhary, S. G., & Asimakopoulos, F. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 170
Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Négrier, S., Chevreau, C., Joly, F., Geoffrois, L., Ladoire, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02218 · Cited by 164
Self-citationFerrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Abu‐Sbeih, H., Tang, T., Lü, Y., Thirumurthi, S., Altan, M., Jazaeri, A. A., Dadu, R., Coronel, E. S., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0502-7 · Cited by 163
Danilova, L., Wang, H., Sunshine, J. C., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 164
Mushti, S. L., Mulkey, F. A., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 166
Pseudoprogression and hyperprogression after checkpoint blockade
Wang, Q., Gao, J., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.018 · Cited by 162
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C., Yelensky, R., Jooss, K. U., & Chan, T. A.-T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 164
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chen, C., Wu, M.-Y., Ng, C. Y., Lu, C., Wu, J., Kao, P., Yang, C., Peng, M., Huang, C., Chang, W.-C., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s163391 · Cited by 164
Metastasis in renal cell carcinoma: Biology and implications for therapy
Gong, J., Maia, M. C., Dizman, N., Govindarajan, A., & Pal, S. K. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.006 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Dysfunctional T cell metabolism in the tumor microenvironment
Beckermann, K. E., Dudzinski, S. O., & Rathmell, J. C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.003 · Cited by 165
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 164
Bang, A., Wilhite, T. J., Pike, L., Cagney, D. N., Aizer, A. A., Taylor, A., Spektor, A., Krishnan, M. S., Ott, P. A., Balboni, T. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.003 · Cited by 159
Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 166
Bullock, A. J., Schlechter, B. L., Fakih, M., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03083-7 · Cited by 160
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158
Sasaki, A., Nakamura, Y., Mishima, S., Kawazoe, A., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Ohtsu, A., Yoshino, T., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00922-8 · Cited by 161
Modeling clear cell renal cell carcinoma and therapeutic implications
Wolf, M. M., Rathmell, W. K., & Beckermann, K. E. (2020) · Oncogene · doi:10.1038/s41388-020-1234-3 · Cited by 170
Xiong, W., Zhang, B., Yu, H., Zhu, L., Yi, L., & Jin, X. (2021) · Advanced Science · doi:10.1002/advs.202100881 · Cited by 157
Lolli, C., Basso, U., Derosa, L., Scarpi, E., Sava, T., Santoni, M., Crabb, S. J., Massari, F., Aieta, M., Conteduca, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10515 · Cited by 157
Coutzac, C., Adam, J., Soularue, É., Collins, M., Racine, A., Mussini, C., Boselli, L., Kamsu-Kom, N., Mateus, C., Charrier, M., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx081 · Cited by 158
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Tan, A. C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M. S., Guminski, A. D., Long, G. V., & Menzies, A. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy330 · Cited by 157
Haas, N. B., Appleman, L. J., Stein, M. N., Redlinger, M., Wilks, M., Xu, X., Onorati, A., Kalavacharla, A., Kim, T., Zhen, C. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2204 · Cited by 156
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 158
Hummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Templeton, A. J., Knox, J. J., Lin, X., Simantov, R., Xie, W., Lawrence, N. J., Broom, R. J., Fay, A. P., Rini, B. I., Donskov, F. N., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.033 · Cited by 155
Self-citationInflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
Collins, M., Michot, J., Danlos, F. X., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx403 · Cited by 153
Gandara, D. R., von Pawel, J., Mazières, J., Sullivan, R., Helland, Å., Han, J., Ponce-Aix, S., Rittmeyer, A., Barlési, F., Kubo, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2027 · Cited by 155
Kim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 158
Xu, J. X., Maher, V. E., Zhang, L., Tang, S. W., Sridhara, R., Ibrahim, A., Kim, G., & Pazdur, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0476 · Cited by 152
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Ogiya, R., Niikura, N., Kumaki, N., Bianchini, G., Kitano, S., Iwamoto, T., Hayashi, N., Yokoyama, K., Oshitanai, R., Terao, M., et al. (2016) · Cancer Science · doi:10.1111/cas.13101 · Cited by 151
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3146 · Cited by 155
The Interplay between Glioblastoma and Its Microenvironment
Dapash, M., Hou, D., Castro, B. A., Lee-Chang, C., & Lesniak, M. S. (2021) · Cells · doi:10.3390/cells10092257 · Cited by 159
The New Era of Immunotherapy in Gastric Cancer
Takei, S., Kawazoe, A., & Shitara, K. (2022) · Cancers · doi:10.3390/cancers14041054 · Cited by 155
Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
Gao, Y., Shi, S., Ma, W., Chen, J., Cai, Y., Ge, L., Li, L., Wu, J., & Tian, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.045 · Cited by 151
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 151
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 151
Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M., Gonzalez, R. C., Clark, J. I., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0522-3 · Cited by 149
Self-citationWang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 157
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 149
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 149
Migliorini, D., Dutoit, V., Allard, M., Grandjean Hallez, N., Marinari, E., Widmer, V., Philippin, G., Corlazzoli, F., Gustave, R., Kreutzfeldt, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz040 · Cited by 147
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 149
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 146
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 149
Atkins, M. B., Clark, J. I., & Quinn, D. I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx151 · Cited by 148
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 147
Lasorsa, F. M., di Meo, N. A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tătaru, O. S., Riccardo Autorino, B., Battaglia, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11041071 · Cited by 146
Reynolds, K. L., & Guidon, A. C. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0359 · Cited by 146
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
